Your browser doesn't support javascript.
loading
An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era.
Pascual-Iglesias, Alejandro; Canton, Javier; Ortega-Prieto, Ana Maria; Jimenez-Guardeño, Jose M; Regla-Nava, Jose Angel.
Afiliação
  • Pascual-Iglesias A; The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain.
  • Canton J; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain.
  • Ortega-Prieto AM; International Institute for Defense and Security (CISDE), 41007 Sevilla, Spain.
  • Jimenez-Guardeño JM; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London SE1 9RT, UK.
  • Regla-Nava JA; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London SE1 9RT, UK.
Pathogens ; 10(8)2021 Aug 14.
Article em En | MEDLINE | ID: mdl-34451494
The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic all over the world. When the virus was first isolated and its genome was sequenced in the early months of 2020, the efforts to develop a vaccine began. Based on prior well-known knowledge about coronavirus, the SARS-CoV-2 spike (S) protein was selected as the main target. Currently, more than one hundred vaccines are being investigated and several of them are already authorized by medical agencies. This review summarizes and compares the current knowledge about main approaches for vaccine development, focusing on those authorized and specifically their immunogenicity, efficacy preventing severe disease, adverse side effects, protection, and ability to cope with emergent SARS-CoV-2 variants.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Pathogens Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Pathogens Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha